Phase 2 Sleep Disorders Trial, Recruiting NCT06274528 Sponsor: University of Minnesota Condition: Sleep Disorders
Back to Sleep Disorders

Phase 2 Sleep Disorders Trial, Recruiting

NCT06274528
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You can be male or female, of any race or ethnicity.
  • You must be 65 years of age or older and able to sign a consent form yourself.
  • You must show no signs of memory or thinking problems based on a standard assessment called the Clinical Dementia Rating (confirm with trial site).
  • You must be willing and able to take part in all study activities.

Who may not be able to join:

  • You have been told you have, or have symptoms of, restless legs syndrome, narcolepsy, or abnormal sleep behaviors (such as acting out dreams).
  • You have a high risk of sleep apnea based on a screening questionnaire, and you do not use a breathing machine (PAP device) at night (confirm with trial site).
  • You have untreated sleep apnea with more than 15 breathing interruptions per hour during sleep.
  • You have sleep apnea that is not well controlled — either because you don't use your breathing machine enough (less than 4 hours a night on most nights) or still have 10 or more breathing interruptions per hour.
  • Your blood test results for a certain protein marker related to brain health fall below a specific level (confirm with trial site).
  • You have had a stroke.
  • You have a history of kidney problems, specifically if your kidneys are not filtering well enough based on a blood test (confirm with trial site).
  • You have a history of liver problems, shown by certain liver enzyme levels being too high on a blood test (confirm with trial site).
  • You have HIV/AIDS.
  • You have had a problem with drug or alcohol misuse in the past 6 months.
  • You regularly drink alcohol 3 or more days a week, where "regularly" means having more than 2 alcoholic drinks within 3 hours of bedtime — though you may still qualify if you agree to reduce your drinking during the study.
  • You have a significant medical, behavioral, or mental health condition, or past surgery, that could affect your safety or the study results.
  • You have a heart condition requiring medication (except for well-controlled high blood pressure), a lung condition, Type 1 diabetes, a neurological or psychiatric condition requiring medication, untreated depression, or you currently smoke tobacco.
  • You take medications that cause drowsiness or that interact with the study drug (lemborexant), unless those medications can be safely stopped.
  • Your routine blood test results come back abnormal.
  • You currently have thoughts of suicide or self-harm.
  • You are not able to speak and understand English.
  • You are currently pregnant or breastfeeding.
  • The study doctor feels, based on your physical exam, that it would not be appropriate for you to join.
  • You have taken part in a clinical trial involving a study drug or device in the 30 days before enrolling in this study.
  • You must not join another drug or device study while taking part in this trial.

For an optional part of the study (spinal fluid sample):

  • You may not be able to take part in this optional procedure if you take blood thinners, have a bleeding disorder, are allergic to lidocaine or certain skin disinfectants, or have had surgery on your spine or central nervous system (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Brendan Lucey, MD, Washington University School of Medicine

Phone: 314-273-0878

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
11 March 2024
Est. completion
31 March 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes plasma pT181/T181 ratio of lemborexant 10 and 20 mg compared to Placebo

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov